Brought to you by 
Hedgepath gets exclusive rights to Mayne's itraconazole formulation for cancer
23 Jul 2018
Executive Summary
Mayne Pharma International Pty. Ltd. (branded and generic drugs; division of Mayne Pharma Group Ltd.) has granted cancer drug developer HedgePath Pharmaceuticals Inc. (formerly Commonwealth Biotechnologies) exclusive US rights to develop and sell its proprietary preclinical formulation of itraconazole for multiple cancers, initially prostate, lung, and skin.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hedgepath gets exclusive rights to Mayne's itraconazole formulation for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice